English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Prostate cancer is one of the popular male genital malignancies worldwide. Several studies have interested on the impact of AMACR expression as indicative and prognostic marker for prostate cancer. Many researches focused on Gleason’s score, PSA and bone scintigraphy in diagnosis and prognosis of prostate cancer. Our aim is to explore the immune histochemical expression of AMACR as additional prognostic and predictive marker in prostate cancer. Material and Methods: Immune histo-chemical staining of AMACR on tissue core biopsies of 49 patients with advanced prostatic cancer and evaluated its expression in relation to Gleason’s score, initial PSA level, nadir PSA level and bone scan as well as biochemical failure to androgen deprivation therapy. Results: we found statistically significant relation between high AMACR expression and high Gleason’s score. Patients with high AMACR expression have a tendency to present with higher level of PSA and positive bone deposits. A tendency was identified for patients with AMACR score 7 to have higher nadir PSA. Biochemical failure was depicted in 71.4% of patients with AMACR Score 7, while patients with AMACR score less than 7 didn't had biochemical failure. On follow up bone scan, ten patients get progression and the AMACR score in these patients was 7. Egyptian J. Nucl. Med., Vol. 15, No. 2, December 2017 53 Conclusion: Our initial results focused on the role of AMACR immune expression as a poor prognostic indicator of prostate cancer, being linked with high Gleason’s score, increased incidence of positive bone metastases and initial high PSA level. In addition, the results highlighted the potential role of AMACR expression as predictive marker of hormonal treatment.

egyptian journal of nuclear medicine

Significance of AMACR Expression as Additive Factor to Bone Scan, Gleason’s Score and PSA in predication of therapy response in advanced Prostatic Carcinoma